Silodosin vs tamsulosin in the management of distal ureteric stones: a prospective randomised study. Arab J Urol 2016;14:12-7.Elgalaly H, Sakr A, Fawzi A, Salem AE, Desoky E, Shahin A, Kamel M: Silodosin vs tamsulosin in the management of distal ureteric stones: a prospective randomised ...
Elgalaly H, Sakr A, Fawzi A, Salem AE, Desoky E, Shahin A, Kamel M: Silodosin vs tamsulosin in the management of distal ureteric stones: a prospective randomised study. Arab J Urol. 2016, 14:12-17. 10.1016/j.aju.2015.11.004
Objective: To compare the efficacy of Tamsulosin, Silodosin and Tadalafil as a medical expulsive therapy for treatment of distal ureteral calculi. Patients and methods: Over a period of 6 months (January 2022 to June 2022) this prospective randomized study was conducted on 170 ...
Dexketoprofen vs. Tamsulosin vs. Silodosin vs. Tadalafil as Medical Expulsive Therapy for Distal Ureteral Stones in Mendoi:10.29271/jcpsp.2021.08.947Gur, MetinUlu, Muhammet BahaettinCaliskan, Suleyman TumerOzturk, KemalAkdeniz, EkremJournal of the College of Physicians & Surgeo...
We compared the efficacy and safety profile of tamsulosin, alfuzosin and silodosin in LUTS due to BPH.doi:10.5173/ceju.2017.924Manohar CmsNagabhushana MKarthikeyan VsSanjay RpKamath AjKeshavamurthy RCent European J UrolCentral European Journal of Urology...
Silodosin, tamsulosin, and prazosin reduced MAP by 11-12% (13-14cmH2O), 17-25% (21-37cmH2O; p<0.05 vs. silodosin), and 27-32% (31-39cmH2O; p<0.05 vs. silodosin). When expressed as a function of effects on MAP, silodosin was more effective (p<0.05) than tamsulosin or prazosin...
Its adverse-event profile reflects that seen with other uroselective 伪-adrenoceptor antagonists with the exception of a relatively high-incidence rate of ejaculatory dysfunction (22 vs 2% with tamsulosin and 28 vs 1% with placebo). This article reviews the preclinical and clinical data concerning ...
The mean changes in the PVR at 6 months were +14.6, +23.7, and +5.7 mL in the naftopidil, tamsulosin, and silodosin groups, respectively; silodosin showed a significant improvement in the PVR at 6 months vs. tamsulosin. With respect to the secondary efficacy variables, the mean ...
for silodosin, 3.53 ml/s for tamsulosin, and 2.93 ml/s for placebo, but the change for silodosin and tamsulosin was not statistically significant versus placebo because of a particularly high placebo response (silodosin vs placebo: = 0.089; tamsulosin vs placebo: = 0.221). ...
end point was 3.77ml/s for silodosin, 3.53ml/s for tamsulosin, and 2.93ml/s for placebo, but the change for silodosin and tamsulosin was not statistically significant versus placebo because of a particularly high placebo response (silodosin vs placebo: =0.089; tamsulosin vs placebo: =0.221). ...